<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://endo.endojournals.org">
<title>Endocrinology Current Issue</title>
<link>http://endo.endojournals.org</link>
<description>Endocrinology RSS feed -- current issue</description>
<prism:coverDisplayDate>Dec  1 2008 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Endocrinology</prism:publicationName>
<prism:issn>0013-7227</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/149/12/5907?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5909?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/149/12/5919?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5922?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/149/12/5932?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5934?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/149/12/5943?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5945?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/149/12/5951?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5952?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5958?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5963?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5972?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5984?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/5996?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6006?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6018?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6028?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6037?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6043?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6053?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6065?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6076?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6084?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6092?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6103?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6113?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6125?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6136?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6146?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6157?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6166?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6176?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6187?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6198?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6207?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6213?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6226?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6236?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6251?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6262?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6272?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6280?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6289?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6300?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6311?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6326?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6336?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6343?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6356?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6366?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6378?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6389?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6399?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6406?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6416?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6425?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6433?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6444?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6449?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6462?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/149/12/6471?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/149/12/6486?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://endo.endojournals.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://endo.endojournals.org/icons/banner/title.gif">
<title>Endocrinology</title>
<url>http://endo.endojournals.org/icons/banner/title.gif</url>
<link>http://endo.endojournals.org</link>
</image>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/149/12/5907?rss=1">
<title><![CDATA[The Skinny on Fat: How Oxysterols May Regulate Functional Glucocorticoids in Adipose Tissue]]></title>
<link>http://endo.endojournals.org/cgi/reprint/149/12/5907?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Yudt, M. R., Freedman, L. P.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1340</dc:identifier>
<dc:title><![CDATA[The Skinny on Fat: How Oxysterols May Regulate Functional Glucocorticoids in Adipose Tissue]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5908</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5907</prism:startingPage>
<prism:section>NEWS &amp; VIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5909?rss=1">
<title><![CDATA[7-Oxysterols Modulate Glucocorticoid Activity in Adipocytes through Competition for 11{beta}-Hydroxysteroid Dehydrogenase Type]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5909?rss=1</link>
<description><![CDATA[
<p>Obesity is associated with an increased risk of diabetes type 2, dyslipidemia, and atherosclerosis. These cardiovascular and metabolic abnormalities are exacerbated by excessive dietary fat, particularly cholesterol and its metabolites. High adipose tissue glucocorticoid levels, generated by the intracellular enzyme 11&beta;-hydroxysteroid dehydrogenase type 1 (11&beta;-HSD1), are also implicated in the pathogenesis of obesity, metabolic syndrome, and atherosclerosis. 11&beta;-HSD1 also interconverts the atherogenic oxysterols 7-ketocholesterol (7KC) and 7&beta;-hydroxycholesterol (7&beta;-HC). Here, we report that 11&beta;-HSD1 catalyzes the reduction of 7KC to 7&beta;-HC in mature 3T3-L1 and 3T3-F442A adipocytes, leading to cellular accumulation of 7&beta;-HC. Approximately 73% of added 7KC was reduced to 7&beta;-HC within 24 h; this conversion was prevented by selective inhibition of 11&beta;-HSD1. Oxysterol and glucocorticoid conversion by 11&beta;-HSD1 was competitive and occurred with a physiologically relevant IC<SUB>50</SUB> range of 450 n<scp>m</scp> for 7KC inhibition of glucocorticoid metabolism. Working as an inhibitor of 11&beta;-reductase activity, 7KC decreased the regeneration of active glucocorticoid and limited the process of differentiation of 3T3-L1 preadipocytes. 7KC and 7&beta;-HC did not activate liver X receptor in a transactivation assay, nor did they display intrinsic activation of the glucocorticoid receptor. However, when coincubated with glucocorticoid (10 n<scp>m</scp>), 7KC repressed, and 7&beta;-HC enhanced, glucocorticoid receptor transcriptional activity. The effect of 7-oxysterols resulted from the modulation of 11&beta;-HSD1 reaction direction, and could be ameliorated by overexpression of hexose 6-phosphate dehydrogenase, which supplies reduced nicotinamide adenine dinucleotide phosphate to 11&beta;-HSD1. Thus, the activity and reaction direction of adipose 11&beta;-HSD1 is altered under conditions of oxysterol excess, and could impact upon the pathophysiology of obesity and its complications.</p>
]]></description>
<dc:creator><![CDATA[Wamil, M., Andrew, R., Chapman, K. E., Street, J., Morton, N. M., Seckl, J. R.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0420</dc:identifier>
<dc:title><![CDATA[7-Oxysterols Modulate Glucocorticoid Activity in Adipocytes through Competition for 11{beta}-Hydroxysteroid Dehydrogenase Type]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5918</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5909</prism:startingPage>
<prism:section>GLUCOCORTICOIDS-CRH-ACTH-ADRENAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/149/12/5919?rss=1">
<title><![CDATA[Estrogen Imprinting: When Your Epigenetic Memories Come Back to Haunt You]]></title>
<link>http://endo.endojournals.org/cgi/reprint/149/12/5919?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Prins, G. S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1266</dc:identifier>
<dc:title><![CDATA[Estrogen Imprinting: When Your Epigenetic Memories Come Back to Haunt You]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5921</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5919</prism:startingPage>
<prism:section>NEWS &amp; VIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5922?rss=1">
<title><![CDATA[Persistent Hypomethylation in the Promoter of Nucleosomal Binding Protein 1 (Nsbp1) Correlates with Overexpression of Nsbp1 in Mouse Uteri Neonatally Exposed to Diethylstilbestrol or Genistein]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5922?rss=1</link>
<description><![CDATA[
<p>Neonatal exposure of CD-1 mice to diethylstilbestrol (DES) or genistein (GEN) induces uterine adenocarcinoma in aging animals. Uterine carcinogenesis in this model is ovarian dependent because its evolution is blocked by prepubertal ovariectomy. This study seeks to discover novel uterine genes whose expression is altered by such early endocrine disruption via an epigenetic mechanism. Neonatal mice were treated with 1 or 1000 &micro;g/kg DES, 50 mg/kg GEN, or oil (control) on d 1&ndash;5. One group of treated mice was killed before puberty on d 19. Others were ovariectomized or left intact, and killed at 6 and 18 months of age. Methylation-sensitive restriction fingerprinting was performed to identify differentially methylated sequences associated with neonatal exposure to DES/GEN. Among 14 candidates, <I>nucleosomal binding protein</I> 1 (<I>Nsbp</I>1), the gene for a nucleosome-core-particle binding protein, was selected for further study because of its central role in chromatin remodeling. In uteri of immature control mice, <I>Nsbp</I>1 promoter CpG island (CGI) was minimally methylated. Once control mice reached puberty, the <I>Nsbp</I>1 CGI became hypermethylated, and gene expression declined further. In contrast, in neonatal DES/GEN-treated mice, the <I>Nsbp</I>1 CGI stayed anomalously hypomethylated, and the gene exhibited persistent overexpression throughout life. However, if neonatal DES/GEN-treated mice were ovariectomized before puberty, the CGI remained minimally to moderately methylated, and gene expression was subdued except in the group treated with 1000 &micro;g/kg DES. Thus, the life reprogramming of uterine <I>Nsbp</I>1 expression by neonatal DES/GEN exposure appears to be mediated by an epigenetic mechanism that interacts with ovarian hormones in adulthood.</p>
]]></description>
<dc:creator><![CDATA[Tang, W.-Y., Newbold, R., Mardilovich, K., Jefferson, W., Cheng, R. Y. S., Medvedovic, M., Ho, S.-M.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0682</dc:identifier>
<dc:title><![CDATA[Persistent Hypomethylation in the Promoter of Nucleosomal Binding Protein 1 (Nsbp1) Correlates with Overexpression of Nsbp1 in Mouse Uteri Neonatally Exposed to Diethylstilbestrol or Genistein]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5931</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5922</prism:startingPage>
<prism:section>CANCER-ONCOGENES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/149/12/5932?rss=1">
<title><![CDATA[Doing Protein Kinase C: Membrane Estrogen Receptor Signaling in a Neural Circuit]]></title>
<link>http://endo.endojournals.org/cgi/reprint/149/12/5932?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Meisel, R. L.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1166</dc:identifier>
<dc:title><![CDATA[Doing Protein Kinase C: Membrane Estrogen Receptor Signaling in a Neural Circuit]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5933</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5932</prism:startingPage>
<prism:section>NEWS &amp; VIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5934?rss=1">
<title><![CDATA[Protein Kinase C Signaling in the Hypothalamic Arcuate Nucleus Regulates Sexual Receptivity in Female Rats]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5934?rss=1</link>
<description><![CDATA[
<p>Rapid membrane-mediated estradiol signaling regulating sexual receptivity requires the interaction of the estrogen receptor (ER)- and the metabotropic glutamate receptor 1a (mGluR1a). A cell signaling antibody microarray revealed that estradiol activated 42 proteins in the arcuate nucleus of the hypothalamus (ARH). To begin an analysis of various signaling pathways, protein kinase A and protein kinase C (PKC)-, whose signaling pathways have been implicated in the estradiol regulation of sexual receptivity, were examined. In the ARH sample, the increase in phospho-protein kinase A could not be confirmed by Western blotting, in either cytosolic or membrane fractions. However, the increase in phosphorylated PKC seen with the pathway array was verified by Western blotting. To study whether rapid estradiol activation of PKC regulates the ARH-medial preoptic nucleus pathway regulating lordosis, &micro;-opioid receptor (MOR) internalization and lordosis reflex were tested. Blocking PKC in ARH with 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]3-(1H-indol-3-yl) maleimide significantly attenuated estradiol-induced MOR internalization. Furthermore, disruption of PKC signaling within the ARH at the time of estradiol treatment significantly diminished the lordosis reflex. Moreover, blocking PKC prevented MOR internalization when the circuit was activated by the mGluR1a agonist, (RS)-3,5-dihydroxyphenylglycine. Activation of PKC with phorbol 12, 13-dibutyrate induced MOR internalization, indicating that PKC was a critical step for membrane ER-initiated mGluR1a-mediated cell signaling and phorbol 12, 13-dibutyrate significantly facilitated the lordosis reflex. Together these findings indicate that rapid membrane ER-mGluR1a interactions activate PKC cell signaling, which regulates female sexual receptivity.</p>
]]></description>
<dc:creator><![CDATA[Dewing, P., Christensen, A., Bondar, G., Micevych, P.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0847</dc:identifier>
<dc:title><![CDATA[Protein Kinase C Signaling in the Hypothalamic Arcuate Nucleus Regulates Sexual Receptivity in Female Rats]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5942</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5934</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/149/12/5943?rss=1">
<title><![CDATA[Antithyroid Drugs Are 65 Years Old: Time for Retirement?]]></title>
<link>http://endo.endojournals.org/cgi/reprint/149/12/5943?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Beck-Peccoz, P.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1349</dc:identifier>
<dc:title><![CDATA[Antithyroid Drugs Are 65 Years Old: Time for Retirement?]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5944</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5943</prism:startingPage>
<prism:section>NEWS &amp; VIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5945?rss=1">
<title><![CDATA[A Low-Molecular-Weight Antagonist for the Human Thyrotropin Receptor with Therapeutic Potential for Hyperthyroidism]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5945?rss=1</link>
<description><![CDATA[
<p>Low-molecular-weight (LMW) antagonists for TSH receptor (TSHR) may have therapeutic potential as orally active drugs to block stimulating antibodies (TsAbs) in Graves&rsquo; hyperthyroidism. We describe an approach to identify LMW ligands for TSHR based on Org41841, a LMW partial agonist for the LH/choriogonadotropin receptor and TSHR. We used molecular modeling and functional experiments to guide the chemical modification of Org41841. We identified an antagonist (NIDDK/CEB-52) that selectively inhibits activation of TSHR by both TSH and TsAbs. Whereas initially characterized in cultured cells overexpressing TSHRs, the antagonist was also active under more physiologically relevant conditions in primary cultures of human thyrocytes expressing endogenous TSHRs in which it inhibited TSH- and TsAb-induced up-regulation of mRNA transcripts for thyroperoxidase. Our results establish this LMW compound as a lead for the development of higher potency antagonists and serve as proof of principle that LMW ligands that target TSHR could serve as drugs in patients with Graves&rsquo; disease.</p>
]]></description>
<dc:creator><![CDATA[Neumann, S., Kleinau, G., Costanzi, S., Moore, S., Jiang, J.-k., Raaka, B. M., Thomas, C. J., Krause, G., Gershengorn, M. C.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0836</dc:identifier>
<dc:title><![CDATA[A Low-Molecular-Weight Antagonist for the Human Thyrotropin Receptor with Therapeutic Potential for Hyperthyroidism]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5950</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5945</prism:startingPage>
<prism:section>TECHNICAL COMMUNICATIONS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/149/12/5951?rss=1">
<title><![CDATA[Insulin-Like Growth Factors and the Brain]]></title>
<link>http://endo.endojournals.org/cgi/reprint/149/12/5951?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[LeRoith, D.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1190</dc:identifier>
<dc:title><![CDATA[Insulin-Like Growth Factors and the Brain]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5951</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5951</prism:startingPage>
<prism:section>MINI-REVIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5952?rss=1">
<title><![CDATA[Mouse Models of Alzheimer's Dementia: Current Concepts and New Trends]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5952?rss=1</link>
<description><![CDATA[
<p>It is lay knowledge now that Alzheimer&rsquo;s dementia (AD) is one of the most devastating diseases afflicting our societies. A major thrust in search for a cure has relied in the development of animal models of the disease. Thanks to progress in the genetics of the rare inherited forms of AD, various transgenic mouse models harboring human mutated proteins were developed, yielding very significant advancements in the understanding of pathological pathways. Although these models led to testing many different new therapies, none of the preclinical successes have translated yet into much needed therapeutic improvements. Further insight into the metabolic disturbances that are probably associated with the onset of the disease may also rely on new animal models of AD involving insulin/IGF-I signaling that could mimic the far most common sporadic forms of AD associated with old age. Combination of models of familial AD that develop severe amyloidosis with those displaying defects in insulin/IGF-I signaling may help clarify the link between putative initial metabolic disturbances and mechanisms of pathological progression.</p>
]]></description>
<dc:creator><![CDATA[Torres-Aleman, I.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0905</dc:identifier>
<dc:title><![CDATA[Mouse Models of Alzheimer's Dementia: Current Concepts and New Trends]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5957</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5952</prism:startingPage>
<prism:section>MINI-REVIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5958?rss=1">
<title><![CDATA[Expanding the Mind: Insulin-Like Growth Factor I and Brain Development]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5958?rss=1</link>
<description><![CDATA[
<p>Signaling through the type 1 IGF receptor (IGF1R) after interaction with IGF-I is crucial to the normal brain development. Manipulations of the mouse genome leading to changes in the expression of IGF-I or IGF1R significantly alters brain growth, such that IGF-I overexpression leads to brain overgrowth, whereas null mutations in either IGF-I or the IGF1R result in brain growth retardation. IGF-I signaling stimulates the proliferation, survival, and differentiation of each of the major neural lineages, neurons, oligodendrocytes, and astrocytes, as well as possibly influencing neural stem cells. During embryonic life, IGF-I stimulates neuron progenitor proliferation, whereas later it promotes neuron survival, neuritic outgrowth, and synaptogenesis. IGF-I also stimulates oligodendrocyte progenitor proliferation although inhibiting apoptosis in oligodendrocyte lineage cells and stimulating myelin production. These pleiotropic IGF-I activities indicate that other factors provide instructive signals for specific cellular events and that IGF-I acts to facilitate them. Studies of the few humans with IGF-I and/or IGF1R gene mutations indicate that IGF-I serves a similar role in man.</p>
]]></description>
<dc:creator><![CDATA[Joseph D'Ercole, A., Ye, P.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0920</dc:identifier>
<dc:title><![CDATA[Expanding the Mind: Insulin-Like Growth Factor I and Brain Development]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5962</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5958</prism:startingPage>
<prism:section>MINI-REVIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5963?rss=1">
<title><![CDATA[Insulin-Like Growth Factors in the Peripheral Nervous System]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5963?rss=1</link>
<description><![CDATA[
<p>IGF-I and -II are potent neuronal mitogens and survival factors. The actions of IGF-I and -II are mediated via the type I IGF receptor (IGF-IR) and IGF binding proteins regulate the bioavailability of the IGFs. Cell viability correlates with IGF-IR expression and intact IGF-I/IGF-IR signaling pathways, including activation of MAPK/phosphatidylinositol-3 kinase. The expression of IGF-I and -II, IGF-IR, and IGF binding proteins are developmentally regulated in the central and peripheral nervous system. IGF-I therapy demonstrates mixed therapeutic results in the treatment of peripheral nerve injury, neuropathy, and motor neuron diseases such as amyotrophic lateral sclerosis. In this review we discuss the role of IGFs during peripheral nervous system development and the IGF signaling system as the potential therapeutic target for the treatment of nerve injury and motor neuron diseases.</p>
]]></description>
<dc:creator><![CDATA[Sullivan, K. A., Kim, B., Feldman, E. L.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1020</dc:identifier>
<dc:title><![CDATA[Insulin-Like Growth Factors in the Peripheral Nervous System]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5971</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5963</prism:startingPage>
<prism:section>MINI-REVIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5972?rss=1">
<title><![CDATA[EGCG Stabilizes p27kip1 in E2-Stimulated MCF-7 Cells through Down-Regulation of the Skp2 Protein]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5972?rss=1</link>
<description><![CDATA[
<p>Loss of p27<sup>Kip1</sup> is associated with a poor prognosis in breast cancer. According to previous findings, a decrease in p27<sup>Kip1</sup> levels is mainly the result of enhanced proteasome-dependent degradation mediated by its specific ubiquitin ligase subunit S-phase kinase protein 2 (Skp2). Epigallocatechin-3-gallate (EGCG), the main constituent of green tea, was found to stabilize p27<sup>Kip1</sup> levels in breast cancer, but whether this effect is mediated through changes in Skp2 expression remains unclear. Here we investigated the mechanisms involved in EGCG&rsquo;s growth inhibition of estrogen-responsive human breast cancer MCF-7 cells. In our results, EGCG increased p27<sup>Kip1</sup> and decreased Skp2 in a time- and dose-dependent manner, suggesting that p27<sup>Kip1</sup> and Skp2 may be involved in the growth inhibition by EGCG in estrogen-stimulated MCF-7 cells. Interestingly, mRNA levels of p27<sup>Kip1</sup> and Skp2 did not significantly change in estrogen-stimulated MCF-7 cells after EGCG treatments. Moreover, overexpression of Skp2 in MCF-7 cells prevented accumulation of p27<sup>Kip1</sup> and promoted resistance to the antiproliferative effects of EGCG. This suggests that the down-regulation of the F-box protein Skp2 is the mechanism underlying p27<sup>Kip1</sup> accumulation. Furthermore, both tamoxifen and paclitaxel significantly and synergistically enhanced the growth inhibition of MCF-7 cells by EGCG through the down-regulation of Skp2 protein. However, the down-regulation of Skp2 was not always correlate with the up-regulation of p27, suggesting that EGCG-dependent Skp2 down-regulation can influence cell growth in several ways. The therapeutic strategies designed to reduce Skp2 may therefore play an important clinical role in treatment of breast cancer cells.</p>
]]></description>
<dc:creator><![CDATA[Huang, H.-C., Way, T.-D., Lin, C.-L., Lin, J.-K.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0408</dc:identifier>
<dc:title><![CDATA[EGCG Stabilizes p27kip1 in E2-Stimulated MCF-7 Cells through Down-Regulation of the Skp2 Protein]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5983</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5972</prism:startingPage>
<prism:section>CANCER-ONCOGENES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5984?rss=1">
<title><![CDATA[Modulation of Runx2 Activity by Estrogen Receptor-{alpha}: Implications for Osteoporosis and Breast Cancer]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5984?rss=1</link>
<description><![CDATA[
<p>The transcription factors Runx2 and estrogen receptor- (ER) are involved in numerous normal and disease processes, including postmenopausal osteoporosis and breast cancer. Using indirect immunofluorescence microscopy and pull-down techniques, we found them to colocalize and form complexes in a ligand-dependent manner. Estradiol-bound ER strongly interacted with Runx2 directly through its DNA-binding domain and only indirectly through its N-terminal and ligand-binding domains. Runx2&rsquo;s amino acids 417&ndash;514, encompassing activation domain 3 and the nuclear matrix targeting sequence, were sufficient for interaction with ER&rsquo;s DNA-binding domain. As a consequence of the interaction, Runx2&rsquo;s transcriptional activation activity was strongly repressed, as shown by reporter assays in COS7 cells, breast cancer cells, and late-stage MC3T3-E1 osteoblast cultures. Metaanalysis of gene expression in 779 breast cancer biopsies indicated negative correlation between the expression of ER and Runx2 target genes. Selective ER modulators (SERM) induced ER-Runx2 interactions but led to various functional outcomes. The regulation of Runx2 by ER may play key roles in osteoblast and breast epithelial cell growth and differentiation; hence, modulation of Runx2 by native and synthetic ER ligands offers new avenues in selective ER modulator evaluation and development.</p>
]]></description>
<dc:creator><![CDATA[Khalid, O., Baniwal, S. K., Purcell, D. J., Leclerc, N., Gabet, Y., Stallcup, M. R., Coetzee, G. A., Frenkel, B.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0680</dc:identifier>
<dc:title><![CDATA[Modulation of Runx2 Activity by Estrogen Receptor-{alpha}: Implications for Osteoporosis and Breast Cancer]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>5995</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5984</prism:startingPage>
<prism:section>CANCER-ONCOGENES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/5996?rss=1">
<title><![CDATA[The Role of Insulin Receptor Signaling in Zebrafish Embryogenesis]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/5996?rss=1</link>
<description><![CDATA[
<p>Insulin receptor (IR) signaling is considered to be important in growth and development in addition to its major role in metabolic homeostasis. The metabolic role of insulin in carbohydrate and lipid metabolism is extensively studied. In contrast, the role of IR activation during embryogenesis is less understood. To address this, we examined the function of the IR during zebrafish development. Zebrafish express two isoforms of IR (<I>insra</I> and <I>insrb</I>). Both isoforms were cloned and show high homology to the human insulin receptor and can functionally substitute for the human IR in fibroblasts derived from <I>insr</I> gene-deleted mice. Gene expression studies reveal that these receptors are expressed at moderate levels in the central nervous system during development. Morpholino-mediated selective knockdown of each of the IR isoforms causes growth retardation and profound morphogenetic defects in the brain and eye. These results clearly demonstrate that IR signaling plays essential roles in vertebrate embryogenesis and growth.</p>
]]></description>
<dc:creator><![CDATA[Toyoshima, Y., Monson, C., Duan, C., Wu, Y., Gao, C., Yakar, S., Sadler, K. C., LeRoith, D.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0329</dc:identifier>
<dc:title><![CDATA[The Role of Insulin Receptor Signaling in Zebrafish Embryogenesis]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6005</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>5996</prism:startingPage>
<prism:section>DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6006?rss=1">
<title><![CDATA[Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic {beta}-Cells and the Involvement of Neuroligin in Insulin Secretion]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6006?rss=1</link>
<description><![CDATA[
<p>The composition of the &beta;-cell exocytic machinery is very similar to that of neuronal synapses, and the developmental pathway of &beta;-cells and neurons substantially overlap. &beta;-Cells secrete -aminobutyric acid and express proteins that, in the brain, are specific markers of inhibitory synapses. Recently, neuronal coculture experiments have identified three families of synaptic cell-surface molecules (neurexins, neuroligins, and SynCAM) that drive synapse formation <I>in vitro</I> and that control the differentiation of nascent synapses into either excitatory or inhibitory fully mature nerve terminals. The inhibitory synapse-like character of the &beta;-cells led us to hypothesize that members of these families of synapse-inducing adhesion molecules would be expressed in &beta;-cells and that the pattern of expression would resemble that associated with neuronal inhibitory synaptogenesis. Here, we describe &beta;-cell expression of the neuroligins, neurexins, and SynCAM, and show that neuroligin expression affects insulin secretion in INS-1 &beta;-cells and rat islet cells. Our findings demonstrate that neuroligins and neurexins are expressed outside the central nervous system and help confer an inhibitory synaptic-like phenotype onto the &beta;-cell surface. Analogous to their role in synaptic neurotransmission, neurexin-neuroligin interactions may play a role in the formation of the submembrane insulin secretory apparatus.</p>
]]></description>
<dc:creator><![CDATA[Suckow, A. T., Comoletti, D., Waldrop, M. A., Mosedale, M., Egodage, S., Taylor, P., Chessler, S. D.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0274</dc:identifier>
<dc:title><![CDATA[Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic {beta}-Cells and the Involvement of Neuroligin in Insulin Secretion]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6017</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6006</prism:startingPage>
<prism:section>DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6018?rss=1">
<title><![CDATA[Fibroblast Growth Factor 21 Corrects Obesity in Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6018?rss=1</link>
<description><![CDATA[
<p>Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a major health concern affecting over 30% of the population, has not been fully explored. Here we report that systemic administration of FGF21 for 2 wk in diet-induced obese and <I>ob</I>/<I>ob</I> mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Although no decrease in total caloric intake or effect on physical activity was observed, FGF21-treated animals exhibited increased energy expenditure, fat utilization, and lipid excretion, reduced hepatosteatosis, and ameliorated glycemia. Transcriptional and blood cytokine profiling studies revealed effects consistent with the ability of FGF21 to ameliorate insulin and leptin resistance, enhance fat oxidation and suppress <I>de novo</I> lipogenesis in liver as well as to activate futile cycling in adipose. Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities.</p>
]]></description>
<dc:creator><![CDATA[Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., Kharitonenkov, A.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0816</dc:identifier>
<dc:title><![CDATA[Fibroblast Growth Factor 21 Corrects Obesity in Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6027</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6018</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6028?rss=1">
<title><![CDATA[Functional Potentiation of Leptin-Signal Transducer and Activator of Transcription 3 Signaling by the Androgen Receptor]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6028?rss=1</link>
<description><![CDATA[
<p>Hypogonadism is associated with increased fat mass and dysregulation of metabolic homeostasis in men. Our previous study revealed that androgen receptor (AR)-null male mice (AR<sup>L-/Y</sup>) develop late-onset obesity and are leptin-resistant. The present study evaluated how hypothalamic AR contributes to central leptin-signal transducer and activator of transcription 3 (STAT3) signaling. We evaluated leptin action in wild-type and AR<sup>L-/Y</sup> mice, the anatomic co-relationship between AR and leptin signaling in the hypothalamus, and the effects of AR on leptin-mediated STAT3 transactivation and nuclear translocation. AR deletion in male mice results in a weaker leptin-induced suppression of food intake and body weight drop even before the onset of overt obesity. In wild-type male but not female mice, AR was highly expressed in various hypothalamic nuclei that also expressed the long-form leptin receptor (OBRB) and co-resided with OBRB directly in the arcuate neurons. In vitro, AR significantly enhanced STAT3-mediated transcription of leptin target genes including POMC and SOCS3. This effect relied on the AR N-terminal activation function-1 (AF-1) domain and was specific to AR in that none of the other sex steroid hormone receptors tested showed similar effects. AR enhanced the low concentrations of leptin-induced STAT3 nuclear translocation <I>in vitro</I>, and AR<sup>L-/Y</sup> mice receiving leptin had impaired STAT3 nuclear localization in the arcuate neurons. These findings indicate that AR in the hypothalamus functions as a regulator of central leptin-OBRB-STAT3 signaling and has a physiological role in energy homeostasis and metabolic regulation in male mice.</p>
]]></description>
<dc:creator><![CDATA[Fan, W., Yanase, T., Nishi, Y., Chiba, S., Okabe, T., Nomura, M., Yoshimatsu, H., Kato, S., Takayanagi, R., Nawata, H.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0431</dc:identifier>
<dc:title><![CDATA[Functional Potentiation of Leptin-Signal Transducer and Activator of Transcription 3 Signaling by the Androgen Receptor]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6036</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6028</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6037?rss=1">
<title><![CDATA[Knockdown of Macrophage Migration Inhibitory Factor Disrupts Adipogenesis in 3T3-L1 Cells]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6037?rss=1</link>
<description><![CDATA[
<p>Obesity is a condition in which adipose tissue mass is expanded. Increases in both adipocyte size and number contribute to enlargement of adipose tissue. The increase in cell number is thought to be caused by proliferation and differentiation of preadipocytes. Macrophage migration inhibitory factor (MIF) is expressed in adipocytes, and intracellular MIF content is increased during adipogenesis. Therefore, we hypothesized that MIF is associated with adipocyte biology during adipogenesis and focused on the influence of MIF on adipogenesis. To examine the effects of MIF on adipocytes, MIF expression in 3T3-L1 preadipocytes was inhibited by RNA interference, and cell differentiation was induced by standard procedures. The triglyceride content of MIF small interfering RNA (siRNA)-transfected 3T3-L1 cells was smaller than that of nonspecific siRNA-transfected cells. In addition, MIF knockdown apparently abrogated increases in adiponectin mRNA levels during differentiation. Gene expression of peroxisome proliferator-activated receptor (PPAR), CCAAT/enhancer binding protein (C/EBP), and C/EBP decreased with MIF siRNA transfection, but C/EBP&beta; expression increased. Cell number and incorporation of 5-bromo-2-deoxyuridine into cells decreased from 1&ndash;3 d and from 14&ndash;20 h, respectively, after induction of differentiation in MIF siRNA-transfected cells, thus suggesting that MIF siRNA inhibits mitotic clonal expansion. Taken together, these results indicated that MIF regulates differentiation of 3T3-L1 preadipocytes, at least partially, through inhibition of mitotic clonal expansion and/or C/EBP expression.</p>
]]></description>
<dc:creator><![CDATA[Ikeda, D., Sakaue, S., Kamigaki, M., Ohira, H., Itoh, N., Ohtsuka, Y., Tsujino, I., Nishimura, M.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0158</dc:identifier>
<dc:title><![CDATA[Knockdown of Macrophage Migration Inhibitory Factor Disrupts Adipogenesis in 3T3-L1 Cells]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6042</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6037</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6043?rss=1">
<title><![CDATA[Functional Characterization of Naturally Occurring Pathogenic Mutations in the Human Leptin Receptor]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6043?rss=1</link>
<description><![CDATA[
<p>We have recently reported the first naturally occurring missense mutations in the leptin receptor (LR) in patients with severe obesity. We have examined the molecular mechanisms by which these extracellular domain mutations disrupt LR signaling. The Ala409Glu mutant receptor is expressed at the cell surface, binds leptin normally but fails to signal to downstream pathways. A409 is present on the surface-exposed region of the Ig-like domain that forms the binding site III for interaction with leptin. This binding site does not appear to contribute to the binding affinity of leptin to its receptor but is critical for receptor activation in response to ligand binding. The Trp664Arg and His684Pro mutations are predicted to impair receptor folding. Both mutants result in a complete inability to signal to downstream pathways despite evidence for some residual cell surface expression and ligand binding. The Arg612His mutant falls in the second subdomain of the high-affinity binding site for leptin, and results in a receptor that shows evidence for intracellular retention but retains some residual signaling. These studies, which represent the first detailed characterization of the functional properties of naturally occurring missense mutations in the human LR, indicate that most such mutations affect receptor folding and expression at the cell surface rather than primarily impairing ligand binding. The exception is Ala409Glu, which interferes with the coupling of ligand binding to receptor activation. Naturally occurring mutations associated with human obesity are valuable tools with which to explore structure/function relationships within the LR.</p>
]]></description>
<dc:creator><![CDATA[Kimber, W., Peelman, F., Prieur, X., Wangensteen, T., O'Rahilly, S., Tavernier, J., Farooqi, I. S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0544</dc:identifier>
<dc:title><![CDATA[Functional Characterization of Naturally Occurring Pathogenic Mutations in the Human Leptin Receptor]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6052</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6043</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6053?rss=1">
<title><![CDATA[Deficiency of TNF{alpha} Converting Enzyme (TACE/ADAM17) Causes a Lean, Hypermetabolic Phenotype in Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6053?rss=1</link>
<description><![CDATA[
<p>Energy homeostasis involves central nervous system integration of afferent inputs that coordinately regulate food intake and energy expenditure. Here, we report that adult homozygous TNF converting enzyme (TACE)-deficient mice exhibit one of the most dramatic examples of hypermetabolism yet reported in a rodent system. Because this effect is not matched by increased food intake, mice lacking TACE exhibit a lean phenotype. In the hypothalamus of these mice, neurons in the arcuate nucleus exhibit intact responses to reduced fat mass and low circulating leptin levels, suggesting that defects in other components of the energy homeostasis system explain the phenotype of <I>Tace</I><sup><I>Zn</I>/<I>Zn</I></sup> mice. Elevated levels of uncoupling protein-1 in brown adipose tissue from <I>Tace</I><sup><I>Zn</I>/<I>Zn</I></sup> mice when compared with weight-matched controls suggest that deficient TACE activity is linked to increased sympathetic outflow. These findings collectively identify a novel and potentially important role for TACE in energy homeostasis.</p>
]]></description>
<dc:creator><![CDATA[Gelling, R. W., Yan, W., Al-Noori, S., Pardini, A., Morton, G. J., Ogimoto, K., Schwartz, M. W., Dempsey, P. J.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0775</dc:identifier>
<dc:title><![CDATA[Deficiency of TNF{alpha} Converting Enzyme (TACE/ADAM17) Causes a Lean, Hypermetabolic Phenotype in Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6064</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6053</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6065?rss=1">
<title><![CDATA[Mechanical Strain Inhibits Adipogenesis in Mesenchymal Stem Cells by Stimulating a Durable {beta}-Catenin Signal]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6065?rss=1</link>
<description><![CDATA[
<p>The ability of exercise to decrease fat mass and increase bone mass may occur through mechanical biasing of mesenchymal stem cells (MSCs) away from adipogenesis and toward osteoblastogenesis. C3H10T1/2 MSCs cultured in highly adipogenic medium express peroxisome proliferator-activated receptor  and adiponectin mRNA and protein, and accumulate intracellular lipid. Mechanical strain applied for 6 h daily inhibited expression of peroxisome proliferator-activated receptor  and adiponectin mRNA by up to 35 and 50%, respectively, after 5 d. A decrease in active and total &beta;-catenin levels during adipogenic differentiation was entirely prevented by daily application of mechanical strain; furthermore, strain induced &beta;-catenin nuclear translocation. Inhibition of glycogen synthase kinase-3&beta; by lithium chloride or SB415286 also prevented adipogenesis, suggesting that preservation of &beta;-catenin levels was important to strain inhibition of adipogenesis. Indeed, mechanical strain inactivated glycogen synthase kinase-3&beta;, which was preceded by Akt activation, indicating that strain transmits antiadipogenic signals through this pathway. Cells grown under adipogenic conditions showed no increase in osteogenic markers runt-related transcription factor (Runx) 2 and osterix (Osx); subsequent addition of bone morphogenetic protein 2 for 2 d increased Runx2 but not Osx expression in unstrained cultures. When cultures were strained for 5 d before bone morphogenetic protein 2 addition, Runx2 mRNA increased more than in unstrained cultures, and Osx expression more than doubled. As such, mechanical strain enhanced MSC potential to enter the osteoblast lineage despite exposure to adipogenic conditions. Our results indicate that MSC commitment to adipogenesis can be suppressed by mechanical signals, allowing other signals to promote osteoblastogenesis. These data suggest that positive effects of exercise on both fat and bone may occur during mesenchymal lineage selection.</p>
]]></description>
<dc:creator><![CDATA[Sen, B., Xie, Z., Case, N., Ma, M., Rubin, C., Rubin, J.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0687</dc:identifier>
<dc:title><![CDATA[Mechanical Strain Inhibits Adipogenesis in Mesenchymal Stem Cells by Stimulating a Durable {beta}-Catenin Signal]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6075</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6065</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6076?rss=1">
<title><![CDATA[Vascular Endothelial Growth Factor Mediates the Estrogen-Induced Breakdown of Tight Junctions between and Increase in Proliferation of Microvessel Endothelial Cells in the Baboon Endometrium]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6076?rss=1</link>
<description><![CDATA[
<p>To assess whether there is a link between estrogen, vascular endothelial growth factor (VEGF), and early aspects of uterine angiogenesis, an acute temporal study was conducted in which ovariectomized baboons were pretreated with VEGF Trap, which sequesters endogenous VEGF, and administered estradiol at time 0 h. Serum estradiol levels approximated 500 pg/ml 4&ndash;6 h after estradiol administration. VEGF mRNA levels in endometrial glandular epithelial and stromal cells were increased to values 6 h after estradiol that were 3.74 &plusmn; 0.99-fold (mean &plusmn; <scp>se</scp>) and 5.70 &plusmn; 1.60-fold greater (<I>P</I> &lt; 0.05), respectively, than at 0 h. Microvessel interendothelial cell tight junctions, which control paracellular permeability, were present in the endometrium at time 0 h, but not evident 6 h after estradiol administration. Thus, microvessel paracellular cleft width increased (<I>P</I> &lt; 0.01, ANOVA) from 5.03 &plusmn; 0.22 nm at 0 h to 7.27 &plusmn; 0.48 nm 6 h after estrogen. In contrast, tight junctions remained intact, and paracellular cleft widths were unaltered in estradiol/VEGF Trap and vehicle-treated animals. Endometrial microvessel endothelial cell mitosis, <I>i.e</I>. percent Ki67<sup>+</sup>/Ki67<sup>&ndash;</sup> immunolabeled endothelial cells, increased (<I>P</I> &lt; 0.05) from 2.9 &plusmn; 0.3% at 0 h to 21.4 &plusmn; 7.0% 6 h after estrogen treatment but was unchanged in estradiol/VEGF Trap and vehicle-treated animals. In summary, the estrogen-induced disruption of endometrial microvessel endothelial tight junctions and increase in endothelial cell proliferation were prevented by VEGF Trap. Therefore, we propose that VEGF mediates the estrogen-induced increase in microvessel permeability and endothelial cell proliferation as early steps in angiogenesis in the primate endometrium.</p>
]]></description>
<dc:creator><![CDATA[Aberdeen, G. W., Wiegand, S. J., Bonagura, T. W., Pepe, G. J., Albrecht, E. D.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0521</dc:identifier>
<dc:title><![CDATA[Vascular Endothelial Growth Factor Mediates the Estrogen-Induced Breakdown of Tight Junctions between and Increase in Proliferation of Microvessel Endothelial Cells in the Baboon Endometrium]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6083</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6076</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6084?rss=1">
<title><![CDATA[The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6084?rss=1</link>
<description><![CDATA[
<p>The menopausal transition is associated with decreased ovarian function and concomitant decline in estrogen production, which may result in physiological effects such as hot flashes, reduced bone mass, and altered lipid profile. It is well established that these unfavorable changes are effectively offset with estrogen therapy (ET) or, in women with a uterus, estrogens in combination with a progestin (hormone therapy). Selective estrogen receptor (ER) modulators (SERMs), which exhibit both ER agonist and antagonist activities depending on the target tissue, have been regarded as offering the potential to provide the benefits of ET and hormone therapy with an improved safety and tolerability profile. To date, no SERM alone has demonstrated an ideal benefit-risk profile for menopausal therapy. The tissue-selective estrogen complex, or the pairing of a SERM with estrogens, may provide an optimal blend of ER agonist and antagonist activities. We evaluated the physiological profile of this novel therapeutic paradigm by using various <I>in vivo</I> models to assess uterine, vasomotor, lipid, and skeletal responses to a tissue-selective estrogen complex partnering bazedoxifene with conjugated estrogens (CE). Bazedoxifene at 3.0 mg/kg effectively antagonized CE-induced uterine stimulation without reversing the positive effects of CE on vasomotor instability. When paired with CE, bazedoxifene at 3.0 mg/kg reduced total cholesterol levels by up to 20% compared with CE alone and significantly increased total bone density relative to control. These preclinical findings showed that the appropriate dose combination of bazedoxifene/CE exhibits positive vasomotor, lipid, and skeletal responses with minimal uterine stimulation.</p>
]]></description>
<dc:creator><![CDATA[Kharode, Y., Bodine, P. V. N., Miller, C. P., Lyttle, C. R., Komm, B. S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0817</dc:identifier>
<dc:title><![CDATA[The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6091</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6084</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6092?rss=1">
<title><![CDATA[Sevelamer Restores Bone Volume and Improves Bone Microarchitecture and Strength in Aged Ovariectomized Rats]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6092?rss=1</link>
<description><![CDATA[
<p>Sevelamer hydrochloride, a noncalcium phosphate binder, has been shown to reduce coronary artery and aortic calcification, and to improve trabecular bone mineral density in hemodialysis patients with chronic kidney disease. Here, we examined whether sevelamer given orally for 12 wk with normal food could restore bone volume (BV) and strength in aged ovariectomized (OVX) rats starting at 4 wk after OVX. Dual-energy x-ray absorptiometry, microcomputerized tomography, and bone histomorphometry analyses showed that OVX animals receiving sevelamer had increased trabecular BV (51%), trabecular number (43%), trabecular thickness (9%), cortical thickness (16%), mineral apposition rate (103%), bone formation rate (25%), and enhanced cortical and trabecular bone mechanical strength as compared with OVX rats. Sevelamer decreased collagen C telopeptide, increased osteocalcin levels, and decreased phosphate and magnesium levels without affecting calcium levels in the blood. Although sevelamer was not absorbed systemically, it stimulated osteoblast differentiation in BM-derived mesenchymal stem cell cultures, as evaluated by alkaline phosphatase positive colony-forming units, and inhibited recombinant human soluble receptor activator of nuclear factor-B ligand-induced osteoclast differentiation, as evaluated by tartrate-resistant acid phosphatase positive cells in bone mineral-hematopoietic stem cell cultures. Surface enhanced laser desorption/ionization time-of-flight mass spectrometry analysis revealed that 69 proteins were differently expressed after OVX, of which 30% (20 of 69) were reversed to sham activity after sevelamer intake. PTH, fibroblast growth factor-23, and cytokine profile in serum were not significantly changed. Together, these results suggest that sevelamer in food increases the BV and improves biomechanical properties of bone in OVX rats.</p>
]]></description>
<dc:creator><![CDATA[Sampath, T. K., Simic, P., Moreno, S., Bukanov, N., Draca, N., Kufner, V., Tikvica, A., Blair, A., Semenski, D., Brncic, M., Burke, S. K., Vukicevic, S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0205</dc:identifier>
<dc:title><![CDATA[Sevelamer Restores Bone Volume and Improves Bone Microarchitecture and Strength in Aged Ovariectomized Rats]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6102</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6092</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6103?rss=1">
<title><![CDATA[The Transcriptional Factor Prolactin Regulatory Element-Binding Protein Mediates the Gene Transcription of Adrenal Scavenger Receptor Class B Type I via 3',5'-Cyclic Adenosine 5'-Monophosphate]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6103?rss=1</link>
<description><![CDATA[
<p>Prolactin regulatory element-binding (PREB) protein is a transcription factor that regulates prolactin promoter activity in the rat anterior pituitary. The PREB protein is not only expressed in the anterior pituitary but also in the adrenal gland. However, the role of PREB in the adrenal gland is not clearly understood. Scavenger receptor class B type I (SR-BI) is a receptor for high-density lipoprotein that mediates the cellular uptake of high-density lipoprotein-cholesteryl ester and is a major route for cholesterol delivery to the steroidogenic pathway in the adrenal gland. In the present study, we have examined the role of PREB in regulating SR-BI. SR-BI expression was found to be regulated by cAMP, which stimulated the expression of PREB in a dose-dependent manner. Conversely, overexpression of PREB using a PREB-expressing adenovirus increased the expression of the SR-BI protein in the adrenocortical cell line Y-1. In addition, PREB induced the expression of the luciferase reporter protein that was under the control of the SR-BI promoter. EMSA showed that PREB mediates its transcriptional effect by binding to the PREB-responsive <I>cis</I>-element of the SR-BI promoter. Finally, we used small interfering RNA to inhibit PREB expression in the Y-1 cells and demonstrated that the knockdown of PREB expression attenuated the effects of cAMP on SR-BI expression. In summary, our data showed that in the adrenal gland, PREB regulates the transcription of the SR-BI gene via cAMP.</p>
]]></description>
<dc:creator><![CDATA[Murao, K., Imachi, H., Yu, X., Cao, W. M., Muraoka, T., Dobashi, H., Hosomi, N., Haba, R., Iwama, H., Ishida, T.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0380</dc:identifier>
<dc:title><![CDATA[The Transcriptional Factor Prolactin Regulatory Element-Binding Protein Mediates the Gene Transcription of Adrenal Scavenger Receptor Class B Type I via 3',5'-Cyclic Adenosine 5'-Monophosphate]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6112</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6103</prism:startingPage>
<prism:section>GLUCOCORTICOIDS-CRH-ACTH-ADRENAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6113?rss=1">
<title><![CDATA[Genes Associated with Membrane-Initiated Signaling of Estrogen and Energy Homeostasis]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6113?rss=1</link>
<description><![CDATA[
<p>During the reproductive cycle, fluctuations in circulating estrogens affect multiple homeostatic systems controlled by hypothalamic neurons. Two of these neuronal populations are arcuate proopiomelanocortin and neuropeptide Y neurons, which control energy homeostasis and feeding. Estradiol modulates these neurons either through the classical estrogen receptors (ERs) to control gene transcription or through a G protein-coupled receptor (mER) activating multiple signaling pathways. To differentiate between these two divergent ER-mediated mechanisms and their effects on homeostasis, female guinea pigs were ovariectomized and treated systemically with vehicle, estradiol benzoate (EB) or STX, a selective mER agonist, for 4 wk, starting 7 d after ovariectomy. Individual body weights were measured after each injection day for 28 d, at which time the animals were euthanized, and the arcuate nucleus was microdissected. As predicted, the body weight gain was significantly lower for EB-treated females after d 5 and for STX-treated females after d 12 compared with vehicle-treated females. Total arcuate RNA was extracted from all groups, but only the vehicle and STX-treated samples were prepared for gene microarray analysis using a custom guinea pig gene microarray. In the arcuate nucleus, 241 identified genes were significantly regulated by STX, several of which were confirmed by quantitative real-time PCR and compared with EB-treated groups. The lower weight gain of EB-treated and STX-treated females suggests that estradiol controls energy homeostasis through both ER and mER-mediated mechanisms. Genes regulated by STX indicate that not only does it control neuronal excitability but also alters gene transcription via signal transduction cascades initiated from mER activation.</p>
]]></description>
<dc:creator><![CDATA[Roepke, T. A., Xue, C., Bosch, M. A., Scanlan, T. S., Kelly, M. J., Ronnekleiv, O. K.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0769</dc:identifier>
<dc:title><![CDATA[Genes Associated with Membrane-Initiated Signaling of Estrogen and Energy Homeostasis]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6124</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6113</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6125?rss=1">
<title><![CDATA[Selectively Filtering Short Wavelengths Attenuates the Disruptive Effects of Nocturnal Light on Endocrine and Molecular Circadian Phase Markers in Rats]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6125?rss=1</link>
<description><![CDATA[
<p>Various physiological processes exhibit a circadian rhythm synchronized to the geophysical light/dark cycle. Our study using a rat model demonstrated that exposure to light at night suppressed the expected nocturnal rise in melatonin, increased plasma corticosterone, and disrupted core clock gene expression in the hypothalamus and the adrenal gland. These effects were prevented by filtration of a 10-nm bandwidth of light between 470 and 480 nm, whereas filtration of light between 452 and 462 nm prevented the rise of corticosterone without restoring normal melatonin secretion or hypothalamic clock gene expression. This is the first demonstration of a wavelength dependency of glucocorticoid secretion and clock gene expression. Our results in an animal model suggest that filtering a narrow bandwidth of light from nocturnal lighting may efficiently attenuate overall disruption of circadian endocrine rhythms and clock gene expression in the hypothalamus and adrenal gland. Because a narrow bandwidth of light is filtered, the color distribution of the illumination source is not altered, and this may be of practical importance for potential future studies in shift workers.</p>
]]></description>
<dc:creator><![CDATA[Rahman, S. A., Kollara, A., Brown, T. J., Casper, R. F.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2007-1742</dc:identifier>
<dc:title><![CDATA[Selectively Filtering Short Wavelengths Attenuates the Disruptive Effects of Nocturnal Light on Endocrine and Molecular Circadian Phase Markers in Rats]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6135</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6125</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6136?rss=1">
<title><![CDATA[The Effects of Apelin on the Electrical Activity of Hypothalamic Magnocellular Vasopressin and Oxytocin Neurons and Somatodendritic Peptide Release]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6136?rss=1</link>
<description><![CDATA[
<p>Apelin, a novel peptide originally isolated from bovine stomach tissue extracts, is widely but selectively distributed throughout the nervous system. Vasopressin and oxytocin are synthesized in the magnocellular neurons of the hypothalamic supraoptic nucleus (SON) and paraventricular nucleus, which are apelin-rich regions in the central nervous system. We made extracellular electrophysiological recordings from the transpharyngeally exposed SON of urethane-anaesthetized rats to assess the role of apelin in the control of the firing activity of identified magnocellular vasopressin and oxytocin neurons <I>in vivo</I>. Apelin-13 administration onto SON neurons via microdialysis revealed cell-specific responses; apelin-13 increased the firing rates of vasopressin cells but had no effect on the firing rate of oxytocin neurons. A direct excitatory effect of apelin-13 on vasopressin cell activity is also supported by our <I>in vitro</I> studies showing depolarization of membrane potential and increase in action potential firing. To assess the effects of apelin-13 on somatodendritic peptide release, we used <I>in vitro</I> release studies from SON explants in combination with highly sensitive and specific RIA. Apelin-13 decreases basal (by 78%; <I>P</I> &lt; 0.05; n = 6) and potassium-stimulated (by 57%; <I>P</I> &lt; 0.05; n = 6) vasopressin release but had no effect on somatodendritic oxytocin release. Taken together, our data suggest a local autocrine feedback action of apelin on magnocellular vasopressin neurons. Furthermore, these data show a marked dissociation between axonal and dendritic vasopressin release with a decrease in somatodendritic release but an increase in electrical activity at the cell bodies, indicating that release from these two compartments can be regulated wholly independently.</p>
]]></description>
<dc:creator><![CDATA[Tobin, V. A., Bull, P. M., Arunachalam, S., O'Carroll, A.-M., Ueta, Y., Ludwig, M.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0178</dc:identifier>
<dc:title><![CDATA[The Effects of Apelin on the Electrical Activity of Hypothalamic Magnocellular Vasopressin and Oxytocin Neurons and Somatodendritic Peptide Release]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6145</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6136</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6146?rss=1">
<title><![CDATA[Kinesin Superfamily-Associated Protein 3 Is Preferentially Expressed in Glutamatergic Neurons and Contributes to the Excitatory Control of Female Puberty]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6146?rss=1</link>
<description><![CDATA[
<p>It was earlier shown that expression of kinesin superfamily-associated protein 3 (KAP3), involved in the neuronal anterograde, microtubule-dependent transport of membrane organelles, increases in the hypothalamus of female rats during the juvenile phase of sexual development. KAP3 mRNA is abundant in the hypothalamus, suggesting that it might be expressed in broadly disseminated neuronal systems controlling neuroendocrine function. The present study identifies one of these systems and provides evidence for an involvement of KAP3 in the excitatory control of female puberty. <I>In situ</I> hybridization and immunohistofluorescence studies revealed that the KAP3 gene is expressed in glutamatergic neurons but not in GABAergic or GnRH neurons. Hypothalamic KAP3 mRNA levels increase during the juvenile period of female prepubertal development, remaining elevated throughout puberty. These changes appear to be, at least in part, estradiol dependent because ovariectomy decreases and estradiol increases KAP3 mRNA abundance. Lowering hypothalamic KAP3 protein levels via intraventricular administration of an antisense oligodeoxynucleotide resulted in reduced release of both glutamate and GnRH from the median eminence and delayed the onset of puberty. The median eminence content of vesicular glutamate transporter 2, a glutamate neuron-selective synaptic protein, and synaptophysin, a synaptic vesicle marker, were also reduced, suggesting that the loss of KAP3 diminishes the anterograde transport of these proteins. Altogether, these results support the view that decreased KAP3 synthesis diminishes GnRH output and delays female sexual development by compromising hypothalamic release of glutamate.</p>
]]></description>
<dc:creator><![CDATA[Choi, J., Ha, C. M., Choi, E. J., Jeong, C. S., Park, J. W., Baik, J.-H., Park, J.-Y., Costa, M. E., Ojeda, S. R., Lee, B. J.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0432</dc:identifier>
<dc:title><![CDATA[Kinesin Superfamily-Associated Protein 3 Is Preferentially Expressed in Glutamatergic Neurons and Contributes to the Excitatory Control of Female Puberty]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6156</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6146</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6157?rss=1">
<title><![CDATA[Evidence that a Protein Kinase A Substrate, Small Heat-Shock Protein 20, Modulates Myometrial Relaxation in Human Pregnancy]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6157?rss=1</link>
<description><![CDATA[
<p>For a successful human pregnancy, the phasic smooth muscle of the myometrium must remain quiescent until labor. Activation of cAMP/cAMP-dependent protein kinase A (PKA) pathways contributes to this quiescence. The small heat-shock protein 20 (HSP20) is a target of PKA, and phosphorylated HSP20 (pHSP20) modulates relaxation of tonic vascular smooth muscle via interaction with actin, independent of myosin dephosphorylation. Our objective was to determine whether relaxation in human myometrium is associated with changes in phosphorylation of HSP20. Myometrium was obtained at elective cesarean. Elevating cAMP with forskolin or rolipram (a phosphodiesterase inhibitor) caused substantial relaxation of spontaneously contracting human myometrial strips, of 92 &plusmn; 4% (mean &plusmn; <scp>sem</scp>, n = 10) and 84 &plusmn; 7% (n = 6), respectively. Subsequent two-dimensional electrophoresis with immunoblotting of strip extracts showed a significant 2.6- and 2.1-fold increase in phosphorylated HSP20 (pHSP20) after forskolin (<I>P</I> &lt; 0.01; n = 5) or rolipram treatment (<I>P</I> &lt; 0.05; n = 4). Noncyclic-nucleotide-mediated relaxation, induced by the calcium channel blocker nifedipine, did not alter pHSP20. Inhibition of PKA with H89 significantly attenuated rolipram-induced relaxation (<I>P</I> &lt; 0.01; n = 4), and partially reduced rolipram-stimulated pHSP20. Total and pHSP20 protein was unchanged in term laboring and nonlaboring myometria. Coimmunoprecipitation studies revealed a specific association of HSP20 with -smooth muscle actin and HSP27, a key regulator of actin filament dynamics. Finally, coimmunofluorescence demonstrated moderate colocalization of HSP20 with -smooth muscle actin in the cytoplasm of laboring myometria. Our data support a novel role for pHSP20 in the modulation of cyclic-nucleotide-mediated myometrial relaxation, through interaction with actin. pHSP20 represents an important new target for future tocolytic therapy.</p>
]]></description>
<dc:creator><![CDATA[Tyson, E. K., MacIntyre, D. A., Smith, R., Chan, E.-C., Read, M.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0593</dc:identifier>
<dc:title><![CDATA[Evidence that a Protein Kinase A Substrate, Small Heat-Shock Protein 20, Modulates Myometrial Relaxation in Human Pregnancy]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6165</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6157</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6166?rss=1">
<title><![CDATA[Analysis of Lysophosphatidic Acid (LPA) Receptor and LPA-Induced Endometrial Prostaglandin-Endoperoxide Synthase 2 Expression in the Porcine Uterus]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6166?rss=1</link>
<description><![CDATA[
<p>Lysophosphatidic acid (LPA), a simple phospholipid-derived mediator with diverse biological actions, acts through the specific G protein-coupled receptors endothelial differentiation gene (EDG) 2, EDG4, EDG7, and GPR23. Recent studies indicate a critical role for LPA receptor signaling in embryo implantation. To understand how LPA acts in the uterus during pregnancy in pigs, we evaluated: 1) spatial and temporal expression of LPA receptors in the uterine endometrium during the estrous cycle and pregnancy and in early-stage concepti, 2) LPA levels in uterine luminal fluids from d 12 of the estrous cycle and pregnancy, 3) effects of steroid hormones on <I>EDG7</I> mRNA levels, and 4) effects of LPA on prostaglandin-endoperoxide synthase 2 (<I>PTGS2</I>) mRNA levels in the uterine endometrium using explant cultures. Of the four receptors, EDG7 was dominant, and its expression was regulated by pregnancy stage and status. <I>EDG7</I> expression was highest on d 12 pregnancy, and localized to the luminal and glandular epithelium, and <I>EDG7</I> mRNA levels were elevated by estrogen in the endometrium. <I>EDG7</I> expression was also detected in concepti of d 12 and 15. LPA with various fatty acyl groups was present in the uterine lumen on d 12 of both the estrous cycle and pregnancy. LPA increased <I>PTGS2</I> mRNA abundance in the uterine endometrium. These results indicate that LPA produced in the uterine endometrium may play a critical role in uterine endometrial function and conceptus development through EDG7-mediated <I>PTGS2</I> expression during implantation and establishment of pregnancy in pigs.</p>
]]></description>
<dc:creator><![CDATA[Seo, H., Kim, M., Choi, Y., Lee, C.-K., Ka, H.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0354</dc:identifier>
<dc:title><![CDATA[Analysis of Lysophosphatidic Acid (LPA) Receptor and LPA-Induced Endometrial Prostaglandin-Endoperoxide Synthase 2 Expression in the Porcine Uterus]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6175</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6166</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6176?rss=1">
<title><![CDATA[Testis Development, Fertility, and Survival in Ethanolamine Kinase 2-Deficient Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6176?rss=1</link>
<description><![CDATA[
<p><I>Ethanolamine kinase 2</I> (<I>Eki2</I>) was previously isolated from a differential expression screen designed to identify candidate genes involved in testis development and differentiation. In mouse, <I>Eki2</I> is specifically up-regulated in Sertoli cells of the developing testis at the time of sex determination. Based on this expression profile, <I>Eki2</I> was considered a good candidate testis-determining gene. To investigate a possible role of <I>Eki2</I> in testis development, we have generated a mouse with targeted disruption of the <I>Eki2</I> gene by using an <I>EGFP</I> replacement strategy. No abnormalities were detected in the <I>Eki2</I>-deficient mice with regard to embryonic and adult testis morphology, differentiation, function, or fertility. Furthermore, no significant differences were observed in litter sizes, pup mortality rates, or distribution of the sexes among the offspring. Ethanolamine kinases are involved in the biosynthesis of phosphatidylethanolamine, a major membrane phospholipid. Expression analysis indicates that the absence of an apparent phenotype in the <I>Eki2</I>-deficient mice may be due to compensation by <I>Eki2</I>-family members or the activation of an alternative pathway to generate phosphatidylethanolamine. Expression of <I>EGFP</I> in this mouse model enabled the isolation of gonad cell populations, providing a useful resource from which to obtain relatively pure early steroidogenic cells for further studies.</p>
]]></description>
<dc:creator><![CDATA[Gustin, S. E., Western, P. S., McClive, P. J., Harley, V. R., Koopman, P. A., Sinclair, A. H.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0584</dc:identifier>
<dc:title><![CDATA[Testis Development, Fertility, and Survival in Ethanolamine Kinase 2-Deficient Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6186</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6176</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6187?rss=1">
<title><![CDATA[Decorin-Mediated Inhibition of Proliferation and Migration of the Human Trophoblast via Different Tyrosine Kinase Receptors]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6187?rss=1</link>
<description><![CDATA[
<p>Decorin (DCN), a decidua-derived TGF&beta;-binding proteoglycan, negatively regulates proliferation, migration, and invasiveness of human extravillous trophoblast (EVT) cells in a TGF&beta;-independent manner. The present study examined underlying mechanisms, in particular possible roles of epidermal growth factor receptor (EGFR), IGF receptor (IGFR)-I, and vascular endothelial growth factor receptor (VEGFR)-2. EVT cell sprouting from first-trimester chorionic villus explants in the presence or absence of TGF&beta;-neutralizing antibody was inhibited with DCN, suggesting its negative regulatory role <I>in situ</I>. Inhibition of migration of the human EVT cell line HTR-8/SVneo in transwells undercoated with fibronectin was stronger when cells were briefly preincubated with DCN at 4 C (known to retard dissociation of receptor-ligand complex) than at 37 C, suggesting possible DCN action by cell membrane binding. Pretreatment of cells with an IGFR-I blocking agent, but not two EGFR blocking agents or a VEGFR blocking agent, significantly abrogated migration inhibitory effects of DCN, suggesting the involvement of IGFR-I but not EGFR or VEGFR in migration inhibition by DCN. On the other hand, pretreatment with either of the EGFR blocking agents, or the VEGFR blocking agent but not the IGFR-I blocking agent, blocked proliferation inhibitory effects of DCN, indicating the roles of EGFR and VEGFR, but not IGFR-I in antiproliferative action of DCN. EVT cells expressed EGFR, IGFR-I, and VEGFR-2. IGFR-I and VEGF-R2 were phosphorylated in the presence of their natural ligands as well as DCN, and these events were blocked by pretreatment with respective receptor blocking agents indicating DCN-mediated activation of these receptors. In conclusion, DCN effects on EVT cells are mediated selectively by multiple tyrosine kinase receptors.</p>
]]></description>
<dc:creator><![CDATA[Iacob, D., Cai, J., Tsonis, M., Babwah, A., Chakraborty, C., Bhattacharjee, R. N., Lala, P. K.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0780</dc:identifier>
<dc:title><![CDATA[Decorin-Mediated Inhibition of Proliferation and Migration of the Human Trophoblast via Different Tyrosine Kinase Receptors]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6197</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6187</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6198?rss=1">
<title><![CDATA[Estrogen Actions in the Male Reproductive System Involve Estrogen Response Element-Independent Pathways]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6198?rss=1</link>
<description><![CDATA[
<p>The estrogen receptor- (ER) acts through multiple pathways, including estrogen response element (ERE)-dependent (classical) and ERE-independent (nonclassical) mechanisms. We previously created a mouse model harboring a two-amino-acid mutation of the DNA-binding domain (E207A, G208A) that precludes direct binding of ER to an ERE. After crossing heterozygous mutant mice with an ER knockout (ERKO) line, it was possible to assess the degree of physiological rescue by the isolated ER nonclassical allele (&ndash;/AA; AA) when compared with ERKO mice (&ndash;/&ndash;) and to wild type (+/+; WT). In male ERKO mice up to 8 months of age, testosterone levels were high, although LH levels were similar to WT. Testosterone was normal in the AA mice, indicating that the AA allele rescues the enhanced testosterone biosynthesis in ERKO mice. Male ERKO mice exhibited distention of the seminiferous tubules as early as 2&ndash;3 months of age as a consequence of decreased water resorption in the efferent ducts. By 3&ndash;4 months of age, ERKO mice had impaired spermatogenesis in approximately 40% of their tubules, and sperm counts and motility declined in association with the histological changes. In the AA mice, histological defects were greatly reduced or absent, and sperm counts and motility were rescued. Levels of aquaporins 1 and 9, which contribute to water uptake in the efferent ducts, were reduced in ERKO mice and partially or fully rescued in AA mice, whereas another water transporter, sodium-hydrogen exchanger-3, was decreased in both ERKO and AA mice. We conclude that non-ERE-dependent estrogen pathways are sufficient to rescue the defective spermatogenesis observed in ERKO mice and play a prominent role in ER action in the testis, including pathways that regulate water resorption and androgen biosynthesis.</p>
]]></description>
<dc:creator><![CDATA[Weiss, J., Bernhardt, M. L., Laronda, M. M., Hurley, L. A., Glidewell-Kenney, C., Pillai, S., Tong, M., Korach, K. S., Jameson, J. L.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0122</dc:identifier>
<dc:title><![CDATA[Estrogen Actions in the Male Reproductive System Involve Estrogen Response Element-Independent Pathways]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6206</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6198</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6207?rss=1">
<title><![CDATA[Dicer1 Is Essential for Female Fertility and Normal Development of the Female Reproductive System]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6207?rss=1</link>
<description><![CDATA[
<p>The ribonuclease III endonuclease, Dicer1 (also known as Dicer), is essential for the synthesis of the 19&ndash;25 nucleotide noncoding RNAs known as micro-RNAs (miRNAs). These miRNAs associate with the RNA-induced silencing complex to regulate gene expression posttranscriptionally by base pairing with 3'untranslated regions of complementary mRNA targets. Although it is established that miRNAs are expressed in the reproductive tract, their functional role and effect on reproductive disease remain unknown. The studies herein establish for the first time the reproductive phenotype of mice with loxP insertions in the <I>Dicer1</I> gene (<I>Dicer1</I><sup><I>fl/fl</I></sup>) when crossed with mice expressing Cre-recombinase driven by the anti-m&uuml;llerian hormone receptor 2 promoter (<I>Amhr2</I><sup><I>Cre</I>/+</sup>). Adult female <I>Dicer1</I><sup><I>fl/fl</I></sup>;<I>Amhr2</I><sup><I>Cre</I>/+</sup> mice displayed normal mating behavior but failed to produce offspring when exposed to fertile males during a 5-month breeding trial. Morphological and histological assessments of the reproductive tracts of immature and adult mice indicated that the uterus and oviduct were hypotrophic, and the oviduct was highly disorganized. Natural mating of <I>Dicer1</I><sup><I>fl/fl</I></sup>;<I>Amhr2</I><sup><I>Cre</I>/+</sup> females resulted in successful fertilization as evidenced by the recovery of fertilized oocytes on d 1 pregnancy, which developed normally to blastocysts in culture. Developmentally delayed embryos were collected from <I>Dicer1</I><sup><I>fl/fl</I></sup>; <I>Amhr2</I><sup><I>Cre</I>/+</sup> mice on d 3 pregnancy when compared with controls. Oviductal transport was disrupted in the <I>Dicer1</I><sup><I>fl/fl</I></sup>;<I>Amhr2</I><sup><I>Cre</I>/+</sup> mouse as evidenced by the failure of embryos to enter the uterus on d 4 pregnancy. These studies implicate Dicer1/miRNA mediated posttranscriptional gene regulation in reproductive somatic tissues as critical for the normal development and function of these tissues and for female fertility.</p>
]]></description>
<dc:creator><![CDATA[Hong, X., Luense, L. J., McGinnis, L. K., Nothnick, W. B., Christenson, L. K.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0294</dc:identifier>
<dc:title><![CDATA[Dicer1 Is Essential for Female Fertility and Normal Development of the Female Reproductive System]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6212</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6207</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6213?rss=1">
<title><![CDATA[Regulation of Bovine Tumor Necrosis Factor-{alpha}-Induced Protein 6 in Ovarian Follicles during the Ovulatory Process and Promoter Activation in Granulosa Cells]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6213?rss=1</link>
<description><![CDATA[
<p>To study the regulation of bovine TNF-induced protein 6 (TNFAIP6) prior to ovulation, preovulatory follicles obtained after the treatment with human chorionic gonadotropin (hCG) were used. RT-PCR analyses showed that levels of TNFAIP6 mRNA were low before hCG but significantly increased after hCG treatment in follicles. Further analyses and immunohistochemistry indicated that this increase in transcript and protein levels occurred in theca and granulosa cells. To investigate molecular mechanisms involved in TNFAIP6 transactivation, the activity of bovine <I>TNFAIP6</I> promoter was studied in granulosa cell cultures. Mutant studies identified the minimal region conferring full-length promoter activity, in which activator protein-1 (AP1) and cAMP response element (CRE) elements were required for promoter activity. Overexpression of dominant-negative AP1 and activating transcription factor/cAMP response element-binding protein (CREB) inhibited forskolin-inducible promoter activity. DNA binding assays demonstrated the importance of AP1 and CRE for activity and identified JunD, FosB, Fra2, CREB1, and CREB2 as being part of the AP1 complex, and FosB, Fra2, and CREB1 for the CRE complex. Chromatin immunoprecipitation assays confirmed binding of these proteins with endogenous <I>TNFAIP6</I> promoter. Treatment with forskolin, prostaglandin E2, and catalytic subunit protein kinase (cPKA) stimulated, but H89, PKA inhibitor peptide, and indomethacin inhibited, <I>TNFAIP6</I> promoter activity and gene expression in granulosa cells. Collectively, this study is the first to describe that the ovulatory process in cows is associated with a gonadotropin-dependent induction of TNFAIP6 in ovarian follicles and provide the molecular basis through which AP1 and CRE sites and PKA activation played important roles in the regulation of TNFAIP6 in granulosa cells.</p>
]]></description>
<dc:creator><![CDATA[Sayasith, K., Bouchard, N., Dore, M., Sirois, J.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0459</dc:identifier>
<dc:title><![CDATA[Regulation of Bovine Tumor Necrosis Factor-{alpha}-Induced Protein 6 in Ovarian Follicles during the Ovulatory Process and Promoter Activation in Granulosa Cells]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6225</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6213</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6226?rss=1">
<title><![CDATA[Platelet-Derived Growth Factor Receptor {beta}-Subtype Regulates Proliferation and Migration of Gonocytes]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6226?rss=1</link>
<description><![CDATA[
<p>Proliferation and migration of gonocytes, the precursors of spermatogonial stem cells, to the germline niche in the basal membrane of the seminiferous tubules, are two crucial events that take place between postnatal d 0.5 (P0.5) and P5.0 in the mouse and involve a selection of the cells that are committed to the germline stem cells lineage. Here we show that from embryonic d 18.0 (E18) and up to P5, the gonocytes express platelet-derived growth factor (PDGF) receptor &beta;-subtype (PDGFR-&beta;) and that during the same time period, the Sertoli cells express PDGF-B and PDGF-D, both ligands for PDGFR-&beta;. Inhibition of the PDGFR-&beta; tyrosine kinase activity during the first five postnatal days provokes a profound reduction of gonocyte number through inhibition of their proliferation and induction of apoptosis. Moreover, we found that PDGFR-&beta; ligands are chemotactic for gonocytes. These data suggest that PDGFR-&beta; activation has the remarkable capability to drive the selection, survival, and migration of the gonocytes from the center of the seminiferous tubules to the testicular germline niche on the basal membrane.</p>
]]></description>
<dc:creator><![CDATA[Basciani, S., De Luca, G., Dolci, S., Brama, M., Arizzi, M., Mariani, S., Rosano, G., Spera, G., Gnessi, L.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0349</dc:identifier>
<dc:title><![CDATA[Platelet-Derived Growth Factor Receptor {beta}-Subtype Regulates Proliferation and Migration of Gonocytes]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6235</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6226</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6236?rss=1">
<title><![CDATA[Transcriptional Response of the Murine Mammary Gland to Acute Progesterone Exposure]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6236?rss=1</link>
<description><![CDATA[
<p>Our mechanistic understanding of progesterone&rsquo;s involvement in murine mammary morphogenesis and tumorigenesis is dependent on defining effector pathways responsible for transducing the progesterone signal into a morphogenetic response. Toward this goal, microarray methods were applied to the murine mammary gland to identify novel downstream gene targets of progesterone. Consistent with a tissue undergoing epithelial expansion, mining of the progesterone-responsive transcriptome revealed the up-regulation of functional gene classes involved in epithelial proliferation and survival. Reassuringly, signaling pathways previously reported to be responsive to progesterone were also identified. Mining this informational resource for rapidly induced genes, we identified "inhibitor of differentiation 4" (Id4) as a new molecular target acutely induced by progesterone exposure. Mammary Id4 is transiently induced during early pregnancy and colocalizes with progesterone receptor (PR) expression, suggesting that Id4 mediates the early events of PR-dependent mammary morphogenesis. Chromatin immunoprecipitation assay detecting direct recruitment of ligand occupied PR to the Id4 promoter supports this proposal. Given that Id4 is a member of the Id family of transcriptional regulators that have been linked to the maintenance of proliferative status and tumorigenesis, the establishment of a mechanistic link between PR signaling and Id4 promises to furnish a wider conceptual framework with which to advance our understanding of normal and abnormal mammary epithelial responses to progestins. In sum, the progesterone-responsive transcriptome described herein not only reinforces the importance of progesterone in mammary epithelial expansion but also represents an invaluable information resource with which to identify novel signaling paradigms for mammary PR action.</p>
]]></description>
<dc:creator><![CDATA[Fernandez-Valdivia, R., Mukherjee, A., Creighton, C. J., Buser, A. C., DeMayo, F. J., Edwards, D. P., Lydon, J. P.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0768</dc:identifier>
<dc:title><![CDATA[Transcriptional Response of the Murine Mammary Gland to Acute Progesterone Exposure]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6250</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6236</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6251?rss=1">
<title><![CDATA[Expression of the Thyroid Hormone Transporters Monocarboxylate Transporter-8 (SLC16A2) and Organic Ion Transporter-14 (SLCO1C1) at the Blood-Brain Barrier]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6251?rss=1</link>
<description><![CDATA[
<p>Thyroid hormones require transport across cell membranes to carry out their biological functions. The importance of transport for thyroid hormone signaling was highlighted by the discovery that inactivating mutations in the human monocarboxylate transporter-8 (MCT8) (<I>SLC16A2</I>) cause severe psychomotor retardation due to thyroid hormone deficiency in the central nervous system. It has been reported that Mct8 expression in the mouse brain is restricted to neurons, leading to the model that organic ion transporter polypeptide-14 (OATP14, also known as OATP1C1/<I>SLCO1C1</I>) is the primary thyroid hormone transporter at the blood-brain barrier, whereas MCT8 mediates thyroid hormone uptake into neurons. In contrast to these reports, we report here that in addition to neuronal expression, MCT8 mRNA and protein are expressed in cerebral microvessels in human, mouse, and rat. In addition, OATP14 mRNA and protein are strongly enriched in mouse and rat cerebral microvessels but not in human microvessels. In rat, Mct8 and Oatp14 proteins localize to both the luminal and abluminal microvessel membranes. In human and rodent choroid plexus epithelial cells, MCT8 is concentrated on the epithelial cell apical surface and OATP14 localizes primarily to the basal-lateral surface. Mct8 and Oatp14 expression was also observed in mouse and rat tanycytes, which are thought to form a barrier between hypothalamic blood vessels and brain. These results raise the possibility that reduced thyroid hormone transport across the blood-brain barrier contributes to the neurological deficits observed in affected patients with MCT8 mutations. The high microvessel expression of OATP14 in rodent compared with human brain may contribute to the relatively mild phenotype observed in Mct8-null mice, in contrast to humans lacking functional MCT8.</p>
]]></description>
<dc:creator><![CDATA[Roberts, L. M., Woodford, K., Zhou, M., Black, D. S., Haggerty, J. E., Tate, E. H., Grindstaff, K. K., Mengesha, W., Raman, C., Zerangue, N.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0378</dc:identifier>
<dc:title><![CDATA[Expression of the Thyroid Hormone Transporters Monocarboxylate Transporter-8 (SLC16A2) and Organic Ion Transporter-14 (SLCO1C1) at the Blood-Brain Barrier]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6261</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6251</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6262?rss=1">
<title><![CDATA[Cold Tolerance in Hypothyroid Rabbits: Role of Skeletal Muscle Mitochondria and Sarcoplasmic Reticulum Ca2+ ATPase Isoform 1 Heat Production]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6262?rss=1</link>
<description><![CDATA[
<p>Brown adipose tissue (BAT) is involved in rat and mice thermoregulation, and heat produced by BAT depends on the concerted action of thyroid hormones and catecholamines. Little is known about cold-induced thermogenesis in mammals that have little or no BAT, such as rabbits. In these animals, thermogenesis primarily occurs in skeletal muscle. In this work, we have studied the effect of cold acclimation (4 C for 10 d) in normal and hypothyroid rabbits. It is known that hypothyroid rats die after a few hours of cold exposure. We now show that, different from rats, hypothyroid rabbits sustain their body temperature and survive after 10 d cold exposure. When compared with rabbits kept at room temperature, the muscles of cold-exposed rabbits showed a dark red color characteristic of oxidative muscle fibers. According to this pattern, we observed that in both normal and hypothyroid rabbits, cold exposure promotes an increase in oxygen consumption by skeletal muscle mitochondria. Moreover, in red muscle, cold acclimation induces an increase in the expression and activity of sarcoplasmic reticulum Ca<sup>2+</sup> ATPase isoform 1 (SERCA1), one of the muscle enzymes involved in heat production. We conclude that rabbit cold tolerance is probably related to increased muscle oxidative metabolism and heat production by SERCA1 and that these changes are not completely dependent on normal thyroid function.</p>
]]></description>
<dc:creator><![CDATA[Arruda, A. P., Ketzer, L. A., Nigro, M., Galina, A., Carvalho, D. P., de Meis, L.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0564</dc:identifier>
<dc:title><![CDATA[Cold Tolerance in Hypothyroid Rabbits: Role of Skeletal Muscle Mitochondria and Sarcoplasmic Reticulum Ca2+ ATPase Isoform 1 Heat Production]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6271</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6262</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6272?rss=1">
<title><![CDATA[Synergistic Up-Regulation of Prostaglandin E Synthase Expression in Breast Cancer Cells by 17{beta}-Estradiol and Proinflammatory Cytokines]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6272?rss=1</link>
<description><![CDATA[
<p>Inflammatory mediators, such as cytokines and prostaglandins, play a fundamental role in estrogen-dependent breast cancer through their ability to up-regulate aromatase expression and subsequent local production of estrogens in the breast. To study the link between estrogens and inflammation further, we examined the regulation of prostaglandin E synthase (PTGES), a key enzyme in the production of prostaglandin E2. We found that 17&beta;-estradiol (E2) rapidly and robustly up-regulates PTGES mRNA and protein levels in estrogen receptor (ER)-positive breast cancer cells through ER recruitment to an essential estrogen response element located in the 5' flanking region of the PTGES gene. PTGES is also up-regulated by the proinflammatory cytokines TNF or IL-1&beta;. Surprisingly, the combination of E2 and cytokines leads to a synergistic up-regulation of PTGES in an ER and nuclear factor-B (NFB)-dependent manner. This is in contrast to the mutual transrepression between ER and NFB that has been well characterized in other cell types. Furthermore, we found enhanced recruitment of ER as well as the NFB family member, p65, to the PTGES estrogen response element by the combination of E2 and TNF compared with either E2 or TNF alone. The synergistic up-regulation of PTGES may result in enhanced prostaglandin E2 production, which in turn may further enhance aromatase expression and production of local estrogens. Our findings suggest that a finely tuned positive feedback mechanism between estrogens and inflammatory factors may exist in the breast and contribute to hormone-dependent breast cancer growth and progression.</p>
]]></description>
<dc:creator><![CDATA[Frasor, J., Weaver, A. E., Pradhan, M., Mehta, K.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0352</dc:identifier>
<dc:title><![CDATA[Synergistic Up-Regulation of Prostaglandin E Synthase Expression in Breast Cancer Cells by 17{beta}-Estradiol and Proinflammatory Cytokines]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6279</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6272</prism:startingPage>
<prism:section>CANCER-ONCOGENES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6280?rss=1">
<title><![CDATA[Pharmacological Demarcation of the Growth Hormone, Gut Motility and Feeding Effects of Ghrelin Using a Novel Ghrelin Receptor Agonist]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6280?rss=1</link>
<description><![CDATA[
<p>The peptide hormone ghrelin exerts a wide spectrum of activities including the stimulation of GH release, feeding, and gastrointestinal motility, purportedly via the activation of a common receptor, GH secretagogue receptor (since renamed the GRLN-R) The aim of the present study was to determine whether these effects can be separated pharmacologically. Tranzyme Pharma (TZP)-101 is a small-molecule agonist with potent binding affinity (inhibitory constant = 16 n<scp>m</scp>) and full agonist activity (EC<SUB>50</SUB> = 29 n<scp>m</scp>, maximum response = 111%) at the human recombinant GRLN-R. Pharmacokinetic profiling of TZP-101 in rat determined a plasma elimination half-life of 99 min and low blood-brain barrier permeability (0.09%). The pharmacological response to TZP-101, administered centrally [intracerebroventricular (icv)] or peripherally (iv), was evaluated in comparison with that of acylated ghrelin. Thus, TZP-101 (iv) accelerated gastric emptying of a liquid meal (2% methylcellulose) similarly to ghrelin (iv). IAlso, TZP-101 (icv) stimulated spontaneous, cumulative food intake in a similar manner to ghrelin (icv). However, unlike ghrelin, TZP-101 did not elicit significant GH release on either central or peripheral administration. Moreover, TZP-101 did not alter ghrelin-induced GH release. n total, these data demonstrate that the GH response can be pharmacologically demarcated from the orexigenic and gastrointestinal responses to ghrelin in rats. The observation that the centrally mediated orexigenic response and the peripherally mediated gastric motility response are pharmacologically associated is consistent with the classification of ghrelin as a brain-gut peptide, whereas the additional action of ghrelin to stimulate GH release (possibly via a distinct signaling pathway) may be considered a complementary mechanism to harmonize somatic growth and body composition with the regulation of energy homeostasis.</p>
]]></description>
<dc:creator><![CDATA[Fraser, G. L., Hoveyda, H. R., Tannenbaum, G. S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0804</dc:identifier>
<dc:title><![CDATA[Pharmacological Demarcation of the Growth Hormone, Gut Motility and Feeding Effects of Ghrelin Using a Novel Ghrelin Receptor Agonist]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6288</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6280</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6289?rss=1">
<title><![CDATA[Prenatal Nicotine Exposure Alters Early Pancreatic Islet and Adipose Tissue Development with Consequences on the Control of Body Weight and Glucose Metabolism Later in Life]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6289?rss=1</link>
<description><![CDATA[
<p>Despite medical advice, 20&ndash;30% of female smokers continue to smoke during pregnancy. Epidemiological studies have associated maternal smoking with increased risk of obesity and type-2 diabetes in the offspring. In the present study, we investigated the impact of prenatal nicotine exposure (3 mg/kg in Sprague Dawley rats via osmotic Alzet minipumps) on the early endocrine pancreas and adipose tissue development in rat pups before weaning. Body weight, fat deposition, food intake and food efficiency, cold tolerance, spontaneous physical activity, glucose utilization, and insulin sensitivity were also examined at adulthood. Prenatal nicotine exposure led to a decrease in endocrine pancreatic islet size and number at 7 d of life (postnatal d 7), which corroborates with a decrease in gene expression of specific transcription factors such as pancreatic and duodenal homeobox 1, Pax-6, Nkx6.1, and of hormones such as insulin and glucagon. The prenatal nicotine exposure also led to an increase in epididymal white adipose tissue weight at weaning (postnatal d 21), and marked hypertrophy of adipocytes, with increased gene expression of proadipogenic transcription factors such as CAAT-enhancer-binding protein-, peroxisome proliferator activated receptor-, and sterol regulatory element binding protein-1C. These early tissue alterations led to significant metabolic consequences, as shown by increased body weight and fat deposition, increased food efficiency on high-fat diet, cold intolerance, reduced physical activity, and glucose intolerance combined with insulin resistance observed at adulthood. These results prove a direct association between fetal nicotine exposure and offspring metabolic syndrome with early signs of dysregulations of adipose tissue and pancreatic development.</p>
]]></description>
<dc:creator><![CDATA[Somm, E., Schwitzgebel, V. M., Vauthay, D. M., Camm, E. J., Chen, C. Y., Giacobino, J.-P., Sizonenko, S. V., Aubert, M. L., Huppi, P. S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0361</dc:identifier>
<dc:title><![CDATA[Prenatal Nicotine Exposure Alters Early Pancreatic Islet and Adipose Tissue Development with Consequences on the Control of Body Weight and Glucose Metabolism Later in Life]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6299</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6289</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6300?rss=1">
<title><![CDATA[Molecular Cloning, Characterization, and Evolutionary Analysis of Estrogen Receptors from Phylogenetically Ancient Fish]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6300?rss=1</link>
<description><![CDATA[
<p>Estrogens are necessary for ovarian differentiation during a critical developmental stage in many vertebrates, and they promote the growth and differentiation of the adult female reproductive system. To understand the evolution of vertebrate estrogen receptors (ESRs) and to evaluate estrogen receptor-ligand interactions in phylogenetically ancient fish, we used PCR techniques to isolate the cDNA encoding ESRs from lungfish, sturgeon, and gar. Sequence analyses indicate that these fishes have two ESRs, ESR1 (ER) and ESR2 (ER&beta;), as previously reported for other vertebrate species, but a second type of ESR2 (ER&beta;2) was not found as has been reported in a number of teleost fishes. Phylogenetic analysis of the ESR sequences indicated that the lungfish ESRs are classified to the tetrapod ESR group, not with the teleost fish ESRs as are the ESRs from gar and sturgeon. Using transient transfection assays of mammalian cells, ESR proteins from these three ancient fishes displayed estrogen-dependent activation of transcription from an estrogen-responsive-element containing promoter. We also examined the estrogenic potential of <I>o</I>,<I>p</I>'-dichloro-diphenyl-trichloroethane (<I>o</I>,<I>p</I>'-DDT) and <I>p</I>,<I>p</I>'-DDT as well as one of its common metabolites, <I>p</I>,<I>p</I>'-dichloro-diphenyl-ethylene (<I>p</I>,<I>p</I>'-DDE) on the ESRs from these fishes. Lungfish ESR1 was less sensitive to DDT/DDE than the ESR1 from the other two fishes. The response of lungfish ESR1 to these pesticides is similar to the pattern obtained from salamander ESR1. These data provide a basic tool allowing future studies examining the receptor-ligand interactions and endocrine-disrupting mechanisms in three species of phylogenetically ancient fish and also expands our knowledge of ESR evolution.</p>
]]></description>
<dc:creator><![CDATA[Katsu, Y., Kohno, S., Hyodo, S., Ijiri, S., Adachi, S., Hara, A., Guillette, L. J., Iguchi, T.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0670</dc:identifier>
<dc:title><![CDATA[Molecular Cloning, Characterization, and Evolutionary Analysis of Estrogen Receptors from Phylogenetically Ancient Fish]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6310</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6300</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6311?rss=1">
<title><![CDATA[Expression of the Transcriptional Repressor ATF3 in Gonadotrophs Is Regulated by Egr-1, CREB, and ATF2 after Gonadotropin-Releasing Hormone Receptor Stimulation]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6311?rss=1</link>
<description><![CDATA[
<p>Stimulation of GnRH receptors enhances expression of activating transcription factor (ATF) 3 in a pituitary gonadotroph cell line. The signaling pathway requires elevated cytosolic Ca<sup>2+</sup> levels and activation of ERK and c-Jun N-terminal protein kinase. The signaling cascade was blocked by overexpression of either MAPK phosphatase (MKP)-1 or MAPK phosphatase-5 that dephosphorylate nuclear ERK and c-Jun N-terminal protein kinase. In addition, ATF3 biosynthesis was impaired after lentiviral-mediated expression of a constitutively active mutant of calcineurin A. Thus, MKP-1, MKP-5, and calcineurin may function as shut-off devices for GnRH receptor signaling. Expression of dominant-negative mutants of early growth response protein (Egr)-1, cAMP response element binding protein (CREB), and ATF2 blocked the biosynthesis of ATF3, indicating that these transcription factors connect the intracellular signaling cascade elicited by activation of GnRH receptors with transcription of the ATF3 gene. This view was corroborated by chromatin immunoprecipitation experiments revealing that Egr-1 and the phosphorylated forms of CREB and ATF2 bound to the 5'-upstream region of the ATF3 gene in buserelin-stimulated gonadotrophs. Together the data indicate that the ATF3 gene is a <I>bona fide</I> target gene of Egr-1, CREB, and ATF2 in gonadotrophs. Moreover, we show that in gonadotrophs ATF3 bound to its own promoter under physiological conditions. The analysis of a lentiviral-transmitted ATF3 promoter/luciferase reporter gene, embedded into the chromatin of the cells, revealed that ATF3 blocked the activity of its own promoter. We additionally identified the chromogranin B gene as <I>bona fide</I> target gene of ATF3 in gonadotrophs.</p>
]]></description>
<dc:creator><![CDATA[Mayer, S. I., Dexheimer, V., Nishida, E., Kitajima, S., Thiel, G.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0251</dc:identifier>
<dc:title><![CDATA[Expression of the Transcriptional Repressor ATF3 in Gonadotrophs Is Regulated by Egr-1, CREB, and ATF2 after Gonadotropin-Releasing Hormone Receptor Stimulation]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6325</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6311</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6326?rss=1">
<title><![CDATA[Modulation of Bone Morphogenetic Protein-9 Expression and Processing by Insulin, Glucose, and Glucocorticoids: Possible Candidate for Hepatic Insulin-Sensitizing Substance]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6326?rss=1</link>
<description><![CDATA[
<p>Bone morphogenetic protein 9 (BMP-9), a member of the TGF-&beta; superfamily predominantly expressed in nonparenchymal liver cells, has been demonstrated to improve glucose homeostasis in diabetic mice. Along with this therapeutic effect, BMP-9 was proposed as a candidate for the hepatic insulin-sensitizing substance (HISS). Whether BMP-9 plays a physiological role in glucose homeostasis is still unknown. In the present study, we show that BMP-9 expression and processing is severely reduced in the liver of insulin-resistant rats. BMP-9 expression and processing was directly stimulated by <I>in situ</I> exposition of the liver to the combination of glucose and insulin and oral glucose in overnight fasted rats. Additionally, prolonged fasting (72 h) abrogated refeeding-induced BMP-9 expression and processing. Previous exposition to dexamethasone, a known inductor of insulin resistance, reduced BMP-9 processing stimulated by the combination of insulin and glucose. Finally, we show that neutralization of BMP-9 with an anti-BMP-9 antibody induces glucose intolerance and insulin resistance in 12-h fasted rats. Collectively, the present results demonstrate that BMP-9 plays an important role in the control of glucose homeostasis of the normal rat. Additionally, BMP-9 is expressed and processed in an HISS-like fashion, which is impaired in the presence of insulin resistance. BMP-9 regulation according to the feeding status and the presence of diabetogenic factors reinforces the hypothesis that BMP-9 might exert the role of HISS in glucose homeostasis physiology.</p>
]]></description>
<dc:creator><![CDATA[Caperuto, L. C., Anhe, G. F., Cambiaghi, T. D., Akamine, E. H., do Carmo Buonfiglio, D., Cipolla-Neto, J., Curi, R., Bordin, S.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0655</dc:identifier>
<dc:title><![CDATA[Modulation of Bone Morphogenetic Protein-9 Expression and Processing by Insulin, Glucose, and Glucocorticoids: Possible Candidate for Hepatic Insulin-Sensitizing Substance]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6335</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6326</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6336?rss=1">
<title><![CDATA[The Environmental Light Influences the Circulatory Levels of Retinoic Acid and Associates with Hepatic Lipid Metabolism]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6336?rss=1</link>
<description><![CDATA[
<p>Environmental light is involved in the regulation of photochemical reaction in mouse retina. It remains unclear whether light-mediated increase in all-trans retinoic acid (ATRA) synthesis in retina will result in altering the circulatory levels of ATRA and regulating downstream gene expression and physiological function. Here we showed circulatory levels of ATRA decreased in mice under constant darkness and elevated by light exposure. Fat gene pancreatic lipase-related protein 2 (<I>mPlrp2</I>) and its partner procolipase (<I>mClps</I>), but not hepatic lipase (<I>mHl</I>), activated in livers for responding to lack of light illuminating. Light-triggered alterations in circulatory ATRA levels regulated ecto-5'-nucleotidase gene expression by retinoic acid receptor retinoic acid receptor- and modulated 5'-AMP levels in blood and were associated with <I>mPlrp2</I> and <I>mClps</I> expression in the livers. Mice deficient in adenosine receptors displayed <I>mPlrp2</I> and <I>mClps</I> expression in livers under 12-h light, 12-h dark cycles. Caffeine blocked adenosine receptors and induced hepatic <I>mPlrp2</I> and <I>mClps</I> expression in wild-type mice. Mice activated in hepatic <I>mPlrp2</I> and <I>mClps</I> expression lowered hepatic and serum lipid levels and markedly elevated circulatory levels of all-trans retinol. Our results suggest environmental light influence hepatic lipid homeostasis by light-modulated retinoic acid signaling associated with <I>mPlrp2</I> and <I>mClps</I> gene expression in livers.</p>
]]></description>
<dc:creator><![CDATA[Pang, W., Li, C., Zhao, Y., Wang, S., Dong, W., Jiang, P., Zhang, J.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0562</dc:identifier>
<dc:title><![CDATA[The Environmental Light Influences the Circulatory Levels of Retinoic Acid and Associates with Hepatic Lipid Metabolism]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6342</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6336</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6343?rss=1">
<title><![CDATA[Effects of Prenatal Dexamethasone Treatment on Physical Growth, Pituitary-Adrenal Hormones, and Performance of Motor, Motivational, and Cognitive Tasks in Juvenile and Adolescent Common Marmoset Monkeys]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6343?rss=1</link>
<description><![CDATA[
<p>Synthetic glucocorticoids such as dexamethasone (DEX) are commonly used to prevent respiratory distress syndrome in preterm infants, but there is emerging evidence of subsequent neurobehavioral abnormalities (<I>e.g.</I> problems with inattention/hyperactivity). In the present study, we exposed pregnant common marmosets (<I>Callithrix jacchus</I>, primates) to daily repeated DEX (5 mg/kg by mouth) during either early (d 42&ndash;48) or late (d 90&ndash;96) pregnancy (gestation period of 144 days). Relative to control, and with a longitudinal design, we investigated DEX effects in offspring in terms of physical growth, plasma ACTH and cortisol titers, social and maintenance behaviors, skilled motor reaching, motivation for palatable reward, and learning between infancy and adolescence. Early DEX resulted in reduced sociability in infants and increased motivation for palatable reward in adolescents. Late DEX resulted in a mild transient increase in knee-heel length in infants and enhanced reversal learning of stimulus-reward association in adolescents. There was no effect of either early or late DEX on basal plasma ACTH or cortisol titers. Both treatments resulted in impaired skilled motor reaching in juveniles, which attenuated in early DEX but persisted in late DEX across test sessions. The increased palatable-reward motivation and decreased social motivation observed in early DEX subjects provide experimental support for the clinical reports that prenatal glucocorticoid treatment impairs social development and predisposes to metabolic syndrome. These novel primate findings indicate that fetal glucocorticoid overexposure can lead to abnormal development of motor, affective, and cognitive behaviors. Importantly, the outcome is highly dependent upon the timing of glucocorticoid overexposure.</p>
]]></description>
<dc:creator><![CDATA[Hauser, J., Knapman, A., Zurcher, N. R., Pilloud, S., Maier, C., Diaz-Heijtz, R., Forssberg, H., Dettling, A., Feldon, J., Pryce, C. R.]]></dc:creator>
<dc:date>2008-11-20</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-0615</dc:identifier>
<dc:title><![CDATA[Effects of Prenatal Dexamethasone Treatment on Physical Growth, Pituitary-Adrenal Hormones, and Performance of Motor, Motivational, and Cognitive Tasks in Juvenile and Adolescent Common Marmoset Monkeys]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>149</prism:volume>
<prism:endingPage>6355</prism:endingPage>
<prism:publicationDate>2008-12-01</prism:publicationDate>
<prism:startingPage>6343</prism:startingPage>
<prism:section>GLUCOCORTICOIDS-CRH-ACTH-ADRENAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/149/12/6356?rss=1">
<title><![CDATA[Prenatal Dexamethasone Impairs Behavior and the Activation of the BDNF Exon IV Promoter in the Paraventricular Nucleus in Adult Offspring]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/149/12/6356?rss=1</link>
<description><![CDATA[
<p>Prenatal manipulations to the hypothalamic-pituitary-adrenal axis are shown to affect auditory responses to an acoustic challenge as well as behavior in adult life. To achieve these results, we examined the effect of prenatal dexamethasone (DEX) treatment in male and female adult rat offspring by assessing body and adrenal weight, anxiety using the elevated plus maze (EPM), and acoustic startle responses as well as the effects of acoustic challenge in the paraventricular nucleus (PVN). DEX male offspring had reduced adrenal gland weight in adult life and demonstrated anxiolytic-like behavior when tested on the EPM. The acoustic startle amplitude in naive DEX-treated male offspring was significantly higher compared with saline (SAL)-treated males and females and DEX-treated females. Wh